Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 3Tumor-Agnostic 2Thoracic 1

Conditions

Breast Neoplasms 16Neoplasms 6Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Advanced Malignant Solid Tumors 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1HER2+ Metastatic Breast Cancer (MBC) 1Cholangiocarcinoma 1Brain Neoplasms 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × neratinib × Clear all
NCT01953926 2024-03-12

SUMMIT

Puma Biotechnology, Inc.

Phase 2 Terminated
582 enrolled 27 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00838539 2018-09-18

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
63 enrolled 26 charts
Tumor-Agnostic

Neoplasms

NCT00146172 2018-09-17

Study Evaluating HKI-272 in Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
73 enrolled 20 charts
Breast

Breast Neoplasms, Neoplasms

NCT00397046 2018-09-14

A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
21 enrolled 13 charts
Tumor-Agnostic

Neoplasms

NCT00300781 2018-08-14

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Puma Biotechnology, Inc.

Phase 2 Completed
136 enrolled 11 charts
Breast

Breast Neoplasms, Neoplasms

NCT00445458 2018-07-26

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Puma Biotechnology, Inc.

Phase 1/2 Completed
110 enrolled 13 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡